Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i

Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine

Filetype[HTM]


This document file type cannot be previewed
  • English

  • Details:

    • Description:
      CDC has begun distribution of a new-generation smallpox vaccine, ACAM2000 (Acambis, Inc., Cambridge, Massachusetts), to civilian laboratory personnel, the military, and state public health preparedness programs. ACAM2000 is a live, vaccinia virus smallpox vaccine that was licensed for use in the United States by the Food and Drug Administration in August 2007 (1).* ACAM2000 will be replacing Dryvax smallpox vaccine (Wyeth Pharmaceuticals, Inc., Marietta, Pennsylvania) because of withdrawal of the Dryvax license. ACAM2000 is a live vaccinia virus derived from plaque purification cloning from Dryvax. The safety data available from the ACAM2000 clinical trials indicate a similar safety profile to Dryvax.
    • Document Type:
    • Place as Subject:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at